Efficacy and Safety Assessment of T2347 Versus Xalacom® in Ocular Hypertensive or Glaucomatous Patients

PHASE3CompletedINTERVENTIONAL

Enrollment

242

Participants

Timeline

Start Date

December 31, 2014

Primary Completion Date

November 30, 2015

Study Completion Date

November 30, 2015

Conditions

Open Angle GlaucomaOcular Hypertension

Interventions

DRUG

T2347

T2347 eye drop solution is presented in SDU. It is supplied in 0.20 ml single use polyethylene containers.

DRUG

Xalacom

Xalacom® 0.01% eye drop solution is supplied in 2.5 ml multidose container.

Trial Locations (1)

Laboratoires Thea, Clermont-Ferrand